Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyurea. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyurea SCHEMBL5329855 | 1.00 | LMNA (1.00) | LMNACA2BLMTSHRPMP22 | |
| Hydroxyurea SCHEMBL4004 | 1.00 | — | — | |
| Hydroxyurea SCHEMBL28164447 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL28783824 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL27583606 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL23274911 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL306433 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL15011410 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL308240 | 0.95 | — | — | |
| Hydroxyurea SCHEMBL28868410 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | claimed |
| WO-2021083310-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | 深圳艾欣达伟医药科技有限公司 | 2021-05-06 | — | — | WO | claimed |
| EP-2291199-A2 | CAPSULATING SYSTEM BINDING TO NUCLEOLIN | Universidade De Coimbra (PT) | 2011-03-09 | — | — | EP | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| US-12472164-B2 | Masitinib for the treatment of sickle cell disease | AB SCIENCE (FR) | 2025-11-18 | — | — | US | disclosed |
| EP-3701258-B1 | A DEVICE FOR ASSESSING CHANGES IN ERYTHROCYTE DEFORMABILITY, SUCH AS ERYTHROCYTE SICKLING TENDENCY | R&R MECHATRONICS INT B V (NL) | 2025-03-12 | — | — | EP | disclosed |
| EP-4061371-B1 | MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE | AB SCIENCE (FR) | 2025-02-19 | — | — | EP | disclosed |
| CN-118986981-A | Quinoline derivatives for the treatment or prophylaxis of cancer | ABIVAX公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12128035-B2 | Activating pyruvate kinase R | NOVO NORDISK HEALTH CARE AG (CH) | 2024-10-29 | — | — | US | disclosed |
| EP-4424295-A1 | PREPARATION METHOD OF A RICE BRAN EXTRACT COMPOSITION AND ITS USE FOR SKIN CARE | CPC Corporation, Taiwan (TW) | 2024-09-04 | — | — | EP | disclosed |
| US-20240173354-A1 | METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS | EXOSTEM BIOTEC LTD. (IL) | 2024-05-30 | — | — | US | disclosed |
| CN-1878514-A | Soft tissue implants and anti-scarring agents | ANGIOTECH INT AG (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1276780-C | Coated surgical patch | ANGIOTECH INT AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | disclosed |
| WO-2006077427-A2 | ANTIVIRAL DRUG COMBINATIONS | MNL PHARMA LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | disclosed |
| CN-1756530-A | Drug delivery from rapid gelling polymer compositions | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| CN-1756571-A | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| CN-1610565-A | Coated surgical patch | ANGIOTECH INT AG (CH) | 2005-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128035-B2 | Activating pyruvate kinase R | PCK1, PDK1, PHKG1 | LMNA 1724/4885CA2 1696/4885BLM 3321/4885 |
| US-12472164-B2 | Masitinib for the treatment of sickle cell disease | MPST, KSR2, HCLS1 | LMNA 1454/4885CA2 2268/4885BLM 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.